Formuepleje A/S’s AstraZeneca AZN Stock Holding History

Formuepleje A/S’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-166,722	Closed	-$22.4M	–	62
2022 Q1	$22.4M	Sell	166,722 -149,994	-47%	-$18M	0.97%	27
2021 Q4	$36.9M	Buy	316,716 +35,233	+13%	+$4.15M	1.4%	27
2021 Q3	$33.8M	Sell	281,483 -194,307	-41%	-$22.6M	1.35%	26
2021 Q2	$57M	Buy	+475,790	New	+$52.2M	2.2%	21

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Formuepleje A/S's AZN Position: Q2 2022 in Review

Formuepleje A/S sold out of AstraZeneca (AZN) in Q2 2022, closing a stake of 166,722 shares — an estimated $22.4M sold.

Formuepleje A/S first reported a position in AZN in Q2 2021 and held it in 4 quarters. The position peaked at $57M in Q2 2021. 1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

Formuepleje A/S reported no remaining AstraZeneca position as of Q2 2022 after selling out during the quarter.
Formuepleje A/S sold 166,722 AstraZeneca shares in Q2 2022, an estimated $22.4M.
Formuepleje A/S first reported a position in AstraZeneca in Q2 2021 and held it in 4 quarters.
Formuepleje A/S's AstraZeneca position peaked at $57M in Q2 2021.
1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Formuepleje A/S's 13F filing for Q2 2022, filed 27 Aug 2026.